Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Curr Opin Lipidol

Retrieve available abstracts of 16 articles:
HTML format

Single Articles

    December 2021
  1. MEDEIROS AM, Bourbon M
    Polygenic contribution for familial hypercholesterolemia (FH).
    Curr Opin Lipidol. 2021;32:392-395.
    PubMed     Abstract available

    October 2021
  2. GILL PK, Hegele RA
    Familial combined hyperlipidemia is a polygenic trait.
    Curr Opin Lipidol. 2021 Oct 22. pii: 00041433-900000000-99252.
    PubMed     Abstract available

  3. MCINTOSH CS, Watts GF, Wilton SD, Aung-Htut MT, et al
    Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations.
    Curr Opin Lipidol. 2021 Oct 15. pii: 00041433-900000000-99253.
    PubMed     Abstract available

  4. GRAHAM DF, Raal FJ
    Management of familial hypercholesterolemia in pregnancy.
    Curr Opin Lipidol. 2021 Oct 6. pii: 00041433-900000000-99256.
    PubMed     Abstract available

    September 2021
    Use of apheresis in the age of new therapies for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2021 Sep 22. pii: 00041433-900000000-99259.
    PubMed     Abstract available

    April 2021
  6. MOHAMED F, Botha TC, Raal FJ
    Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
    Curr Opin Lipidol. 2021 Apr 20. pii: 00041433-900000000-99277.
    PubMed     Abstract available

    February 2021
  7. CHORA JR, Bourbon M
    Pharmacogenomics of statins and familial hypercholesterolemia.
    Curr Opin Lipidol. 2021 Feb 10. pii: 00041433-900000000-99283.
    PubMed     Abstract available

    October 2020
  8. YEANG C, Willeit P, Tsimikas S
    The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000713.
    PubMed     Abstract available

  9. IBRAHIM S, Reeskamp LF, Stroes ESG, Watts GF, et al
    Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods.
    Curr Opin Lipidol. 2020 Oct 6. doi: 10.1097/MOL.0000000000000714.
    PubMed     Abstract available

    September 2020
  10. WOLSKA A, Yang ZH, Remaley AT
    Hypertriglyceridemia: new approaches in management and treatment.
    Curr Opin Lipidol. 2020 Sep 29. doi: 10.1097/MOL.0000000000000710.
    PubMed     Abstract available

    June 2020
  11. SORAN H, Cooper JA, Durrington PN, Capps N, et al
    Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register.
    Curr Opin Lipidol. 2020 Jun 28. doi: 10.1097/MOL.0000000000000692.
    PubMed     Abstract available

  12. BELANGER AM, Akioyamen L, Alothman L, Genest J, et al
    Evidence for improved survival with treatment of homozygous familial hypercholesterolemia.
    Curr Opin Lipidol. 2020 Jun 8. doi: 10.1097/MOL.0000000000000686.
    PubMed     Abstract available

    April 2020
  13. BRANDTS J, Dharmayat KI, Ray KK, Vallejo-Vaz AJ, et al
    Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000675.
    PubMed     Abstract available

  14. BAJAJ A, Cuchel M
    Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Curr Opin Lipidol. 2020 Apr 22. doi: 10.1097/MOL.0000000000000677.
    PubMed     Abstract available

    January 2020
  15. D'ERASMO L, Di Costanzo A, Arca M
    Autosomal recessive hypercholesterolemia: update for 2020.
    Curr Opin Lipidol. 2020 Jan 31. doi: 10.1097/MOL.0000000000000664.
    PubMed     Abstract available

    December 2019
  16. HOLVEN KB, Ulven SM, Bogsrud MP
    Editorial Comment: Hyperlipidaemia and cardiovascular disease and impact of early cholesterol accumulation.
    Curr Opin Lipidol. 2019;30:490-493.

Thank you for your interest in scientific medicine.

AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.